Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …

Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs)
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …

Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due
to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK …